Alright, let's recap- in just a short time AMBS went from owning a small IP portfolio on MANF to where we are today. So where are we exactly? Right now our CEO is amongst the world's elite in the Alzheimer's space. We have a diagnostic which is in the running to be the first blood diagnostic in this space. We are still on track to be commercialized this year for trials. This is a stepping stone for the world market. By gaining accreditation with the trails will gain not only exposure but acceptance within the health care space. By just being in the middle of this conference the main players are taking note. It's not time to expose the agenda just yet. Why? Well in the middle of the conference is also big pharma (where we all will make our money from AMBS- I mean real money). Gerald has managed to be in the same room as them for years now. At first he was not known and was paid no attention to. Now these guys are seeing him build from what was a meek IP portfolio to it being way more extensive. They have seen a progression. He now has a diagnostic which is being primed for other applications. He has acquired a phase 2b drug. Positioning the study to be submitted, Identified reimbursement codes, putting together applications for various orphan designations, aligning a program diabetes, set up alliances with key incubator's which will not only develop MANF and Lympro but identify future therapies and technologies, moved the lab to Jansen (huge), opened up Geneva offices, solidified a powerful board of directors, has 18 employees working to further develop the plan, has cash in the books, access to $20 million more dollars and will receive an additional $5 million dollars in new warrant proceeds. Remember in the filings a bit ago when JP Morgan mentioned they may now buy in addition to another major fund making the same declaration? People are paying attention. He now is in the middle of the world's elite including big pharma and they all see what he has done. He is in talks for a partnership which he has publicly stated. Imagine if he would of done a partnership a year ago. How much shareholder would have been lost? Jason napadano has a price target of .20. This does not include eltropozine or the orphan application or reimbursement or a partnership, or a diabetes program. Some expectations that we have are off- not solid thinking... Would be like telling the other team what you are about to call. The price isn't down because of the conference, it is down because we are selling!
News 
Market Data 
Discover 
AI
